Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
These factors highlight the need and are driving demand for our decentralized cell therapy approach.
- These factors highlight the need and are driving demand for our decentralized cell therapy approach.
- In parallel to progressing our decentralized Octomera platform, the Company’s most advanced oncology therapeutic in development continues to make significant advances in terms of decentralized GMP production and proof of concept with respect to efficacy and safety.
- We are very appreciative of Metalmark for supporting us through the biotech winter and seeing our decentralized vision for the future.
- To learn more, please visit our website .